Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial
Johns Hopkins University · Johns Hopkins Medicine · +1 more institution
Abstract
Cancer patients often develop chronic, clinically significant symptoms of depression and anxiety. Previous studies suggest that psilocybin may decrease depression and anxiety in cancer patients. The effects of psilocybin were studied in 51 cancer patients with life-threatening diagnoses and symptoms of depression and/or anxiety. This randomized, double-blind, cross-over trial investigated the effects of a very low (placebo-like) dose (1 or 3 mg/70 kg) vs. a high dose (22 or 30 mg/70 kg) of psilocybin administered in counterbalanced sequence with 5 weeks between sessions and a 6-month follow-up. Instructions to participants and staff minimized expectancy effects. Participants, staff, and community observers…
Citation impact
- FWCI
- 94.60
- Percentile
- 100%
- References
- 54
Authors
8- RRRoland R. GriffithsCorresponding
Johns Hopkins University, Johns Hopkins Medicine
- MWMatthew W. Johnson
Johns Hopkins University, Johns Hopkins Medicine
- MAMichael A. Carducci
Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center
- AUAnnie Umbricht
Johns Hopkins University, Johns Hopkins Medicine
- WAWilliam A. Richards
Johns Hopkins University, Johns Hopkins Medicine
Topics & keywords
- Psilocybin
- Anxiety
- Mood
- Psychology
- Psychiatry
- Randomized controlled trial
- Placebo
- Clinical psychology